Tat Ka Wai Hong Pharmaceutical Group (Stock Code: 301126), as a key player in China’s pharmaceutical and healthcare industry, has established a distinctive pharmaceutical ecosystem by building an integrated “R&D-Production-Distribution-Retail” industrial chain. Leveraging the synergistic development of its specialized subsidiaries, the Group has formed a comprehensive business structure encompassing drug research and development, intelligent manufacturing, smart logistics, and professional pharmacy services.

In the field of R&D innovation, the Group’s subsidiary Hunan Zhongjia Biopharmaceutical Co., Ltd. specializes in the development of innovative biologic drugs with established comprehensive drug development platforms, while Tat Ka Wai Hong Regenerative Medicine Research Institute Co., Ltd. focuses on stem cell therapy research – these two research institutions jointly drive the Group’s innovative drug development progress.

The manufacturing segment operates two GMP-certified production bases: Dajia Weikang Biopharmaceutical (recognized as a Hunan Province Intelligent Manufacturing Benchmark) and Tianji Caotang Pharmaceutical (a provincial-level technology center). Equipped with 9 modern production lines capable of manufacturing various dosage forms including herbal extracts, solid preparations, and oral liquids, the facilities hold over 100 drug approvals and possess comprehensive pharmaceutical production capabilities.

In the pharmaceutical distribution sector, Hunan Tat Ka Wai Hong Pharmaceutical Co., Ltd., recognized as one of China’s Top 100 Pharmaceutical Commercial Enterprises, operates an advanced intelligent logistics system that provides efficient drug distribution services for the Group. The retail segment is spearheaded by Hunan Tat Ka Wai Hong Pharmaceutical Industry Co., Ltd. (Stock Code: 301126), which manages an extensive nationwide network of nearly 2,000 chain pharmacies.

Additionally, the Group has established regional pharmacy chains including Ningxia Delixin, Yinchuan Meihetai, Shanxi Simaile, Hainan Hongchuntang, and Beijing Zhengjitang, forming a comprehensive national retail network. Each subsidiary maintains distinctive operational characteristics – for instance, Hainan Hongchuntang specializes in traditional Chinese medicine retail, while Beijing Zhengjitang operates large-scale drug supermarket formats.

Leveraging its integrated industrial ecosystem and professional operations, Tat Ka Wai Hong Group has emerged as an industry benchmark, with multiple subsidiaries earning national industry accolades. Looking ahead, the Group will continue to optimize resource allocation, strengthen innovation-driven development, and remain committed to making greater contributions to the high-quality growth of the pharmaceutical and healthcare industry.